A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects by Jennifer Brown et al.
Brown et al. AIDS Research and Therapy 2014, 11:14
http://www.aidsrestherapy.com/content/11/1/14METHODOLOGY Open AccessA genotypic HIV-1 proviral DNA coreceptor
tropism assay: characterization in viremic subjects
Jennifer Brown1*, Harold Burger2, Barbara Weiser2, Richard B Pollard1, Xiao-Dong Li2, Lynell J Clancy1,
Russell E Baumann3, Amy A Rogers3, Hasnah B Hamdan3, Rick L Pesano3 and Ron M Kagan3Abstract
Background: HIV-1 coreceptor tropism testing is used to evaluate eligibility for CCR5 antagonist therapy. However,
HIV-1 RNA-based tests are not suitable for virologically suppressed patients, therefore the use of proviral DNA
tropism testing has been investigated. We describe a novel proviral DNA-based genotypic tropism assay and
compare its performance to that of a sensitive HIV-1 RNA-based genotypic test.
Methods: Tropism was determined using HIV-1 plasma RNA and proviral DNA from 42 paired samples from
patients with plasma viral loads ≥1000 HIV-1 RNA copies/mL. Proviral DNA sample types included whole blood,
separated peripheral blood mononuclear cells resuspended in phosphate-buffered saline and peripheral blood
mononuclear cells resuspended in spun plasma. The HIV-1 envelope V3 region was PCR-amplified, sequenced in
triplicate, and analyzed for tropism with the geno2pheno algorithm using a 10% false-positive rate (FPR).
Results: Amplicons were obtained from proviral DNA and plasma RNA in 41/42 samples. Tropism predictions were
highly concordant (93%–98%) between proviral DNA and plasma RNA, regardless of the proviral DNA isolation
method. Non-R5 proviral DNA results were obtained for 100% of patients with detectable non-R5 plasma HIV-1 RNA
results. Geno2pheno FPRs for proviral DNA and plasma RNA were highly correlated (Spearman rho = 0.86).
Conclusions: Our findings demonstrate that proviral DNA tropism determinations from whole blood or peripheral
blood mononuclear cells were highly concordant with plasma HIV-1 RNA tropism determinations. This assay may
be useful for screening virologically suppressed patients for CCR5-antagonist eligibility and for research purposes.
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Human immunodeficiency virus type 1 (HIV-1) requires
contact with two receptors to gain entry to host cells
and initiate infection: CD4 is the primary receptor and
the chemokine receptors CCR5 and CXCR4 serve as
secondary or co-receptors [1]. HIV-1 tropism refers to
the co-receptors utilized by the virus and can be classi-
fied as R5, or X4 [1,2]. The major viral determinant of
HIV-1 tropism is the V3 region of the envelope protein
gp120, the portion of the viral envelope that interacts
with the CCR5 and CXCR4 receptors [1-6]. The accurate
determination of tropism is clinically important because
CCR5 antagonists such as maraviroc are recommended* Correspondence: jennifer.brown@ucdmc.ucdavis.edu
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unless otherwise stated.only for HIV-1-infected individuals harboring exclusively
CCR5-tropic virus.
Most tropism tests utilize plasma HIV-1 RNA to de-
termine tropism in viremic, HIV-1 infected patients.
Genotypic and phenotypic tropism assays of plasma
HIV-1 are available as clinical tests and are recom-
mended in US and European guidelines [7-9]. However,
there is now increased emphasis on using HIV-1 proviral
DNA (pvDNA) to ascertain tropism. Plasma viral RNA
represents currently replicating HIV-1, while pvDNA is
intracellular viral DNA that represents a population of
archived virus [7-10]. pvDNA can be extracted from the
blood of HIV-1 patients with undetectable RNA viral
loads in plasma [10,11]. This permits tropism testing to
extend to virologically suppressed patients on effective
antiretroviral regimens, who may be candidates forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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men switches or simplification.
Here we evaluated a genotypic test for proviral tropism
determination based on sequencing HIV-1 pvDNA en-
coding the V3 region. HIV-1 proviral tropism was first
determined in blood samples obtained from a diverse,
well-characterized group of viremic patients followed at
the Center for AIDS Research, Education and Services
(CARES) in Sacramento, CA. We then evaluated con-
cordance of tropism predictions using pvDNA and
plasma viral RNA obtained from paired specimens.
Results
HIV-1 V3 loop amplicons were successfully obtained from
both pvDNA and plasma RNA in 41 of the 42 HIV-1–
positive samples (98%). No HIV-1–negative control sam-
ples yielded amplification products. The median subject
age was 40 years old (IQR: 31–46), and most (40/42) sub-
jects were male. Subjects had a median plasma HIV-1 viral
load of 4.3 (IQR: 3.3, 5.0) log10 copies/mL and a median of
352 (IQR: 192, 617) CD4+ T-cells/μL.
Of the 41 patients with successfully amplified HIV-1
RNA and pvDNA, 14 (34%) had non-R5 results (X4 –
tropic virus detected) on RNA testing (Table 1). Relative
to the plasma RNA test, the pvDNA test was 100% sen-
sitive for non-CCR5 virus (14/14) regardless of the sam-
ple types used for DNA extraction. However, pvDNA
testing resulted in additional non-CCR5 predictions
using whole blood (n = 3), PBMCs (n = 2), and PBMCs
resuspended in plasma (n = 1). Phylogenetic tree analysis
of the five samples that had at least one discordant result
between sample types showed no evidence of inter-
sample contamination (Figure 1, Additional file 1: Figure
S1 and Additional file 2: Figure S2). The replicate RNA
and pvDNA sequences for each respective patient were clus-
tered together. For sample 49 (RNA: R5, pvDNA whole
blood: X4) the three RNA-derived V3 sequences were found
in a cluster that was divergent from the pvDNA sequences,
indicative of a distinct viral quasispecies in the plasma com-
partment (Figure 1A). Likewise, the plasma RNA sequences
for sample 26 (concordant R5) also diverged from the pvDNA
sequences for this patient (Additional file 1: Figure S1). TheTable 1 Tropism prediction concordance between 3 proviral D
samples from 41 HIV-1 positive patients
pvDNA source X4, No. (%) Conc
Test Refd
Whole blood (Tube 1a) 17 (41) 14 (34)
PBMCs (Tube 2b) 16 (39) 14 (34)
PBMCs + Plasma (Tube 3) 15 (37) 14 (34)
aSensitivity is defined as concordant X4 results between the test and reference met
bSpecificity is defined as concordant R5 results between the test and reference met
cKappa: a measure of inter-rater agreement: 0.41-0.60: moderate agreement; 0.61-0
dPlasma RNA testing was used as the reference method for all proviral DNA tests.V3 sequences for sample 18 (concordant X4) were also
divided between two divergent clusters (Additional file 1:
Figure S1). For sample 35, the PBMC-derived (X4) V3
sequences branched separately from the whole blood
(R5) and plasma RNA (R5) V3 sequences (Figure 1B).
Thus, pvDNA testing yielded a higher proportion of
non-CCR5 predictions than did RNA testing (Table 1).
pvDNA testing showed exclusively CCR5 tropism in
plasma and whole blood from 24 (56%) patients. Trop-
ism predictions were highly concordant (93% to 98%)
between pvDNA and plasma RNA, regardless of the
sample type used for pvDNA isolation (Table 1).
The average geno2pheno FPRs for the replicate pvDNA
and plasma RNA tropism determinations were strongly
correlated. The Spearman rho correlation coefficient was
0.94 (95% CI: 0.90 – 0.97) for whole blood vs plasma
RNA. There was a higher degree of variability between the
FPRs for pvDNA isolated from PBMCs and from PBMCs
resuspended in plasma compared to plasma RNA, with
Spearman correlation coefficients of 0.86 in both cases
(95% CIs: 0.76 – 0.92 and 0.75 – 0.92). The FPRs for
the two PBMC sample types were highly correlated
(Spearman rho = 0.96; 95% CI: 0.93 – 0.98).
Patients harboring non-CCR5 virus tend to have lower
CD4+ cell counts than patients harboring exclusively
CCR5 virus [12,13]. Although these differences were not
statistically significant (Mann–Whitney test, p = 0.16) in
our study owing to the small sample size, median (IQR)
CD4+ counts were lower among non-CCR5 subjects
(median, 316; IQR, 77–418 cells/μL) than in CCR5 sub-
jects (median, 384; IQR, 212–687 cells/μL).
Discussion
We report a novel genotypic pvDNA tropism assay that
is based on population sequencing of the V3 region of
HIV-1 pvDNA. Using paired, freshly drawn samples, we
found high concordance in tropism predictions made
using pvDNA and plasma RNA. This finding is consist-
ent with the results of other studies, despite differing
methods for determining tropism via HIV-1 envelope V3
region sequencing [10,14,15]. In addition, recent studies
have also demonstrated a high degree of concordanceNA (pvDNA) sample types and plasma RNA in paired
ordance Sensitivitya Specificityb Kappac
93% 100% 89% 0.85
95% 100% 93% 0.90
98% 100% 96% 0.95
hods/reference method X4s.
hods/reference method R5s.
.80: good agreement; 0.81 – 1.0 excellent agreement.
Figure 1 Phylogenetic analysis of four samples with discordant tropism results. A: samples 49 and 45. B: samples 34 and 35. Circles: V3
sequences from RNA; triangles: pvDNA V3 sequences from whole blood; squares: pvDNA V3 sequences from PBMCs.
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HIV-1 subtype C and HIV-2 [16,17]. Taken together,
these findings support the use of pvDNA tropism testing
as an alternative to RNA tropism testing.
Notably, we observed a high degree of concordance re-
gardless of whether the pvDNA was extracted from
whole blood or from PBMCs (either concentrated or re-
suspended in PBS). This is significant because, while
whole blood may be the most convenient specimen type
for tropism testing in the clinical setting, frozen PBMCs
may be more favorable for research studies on archived
specimens. Previous studies have shown that CXCR4-
tropic virus is detected slightly more often with pvDNA
than with plasma RNA [12,15,18]. This is because
pvDNA comprises a heterogeneous population of ar-
chived genomes, whereas plasma RNA represents cur-
rently replicating HIV-1. Among the samples evaluated
in this study, CXCR4-predicted sequences also were de-
tected more often in pvDNA than in plasma RNA.
Although most V3 sequences were well-conserved be-
tween the plasma and the PBMC compartments, some
samples showed a much higher degree of diversity, with
distinct subpopulations appearing in divergent clusters.A previous study that used ultradeep sequencing analysis
of the V3 loop found that concordance between plasma
and PBMC tropism was CD4+ −dependent, with 100% con-
cordance when the count was above 350 cells/μL but only
74% when the count was below 50 cells/μL [19]. In the
current study, the median CD4+ count was 352 cells/μL,
consistent with the high level of observed concordance. One
of three discordant samples (pvDNA non-R5, plasma RNA
R5) had a CD4+ count below 350 cells/uL (195 cells/uL).
Current guidelines from Europe endorse the use of V3
loop sequencing of pvDNA to determine tropism, particu-
larly for patients with low-level viremia or with viral sup-
pression [9]. From a clinical standpoint, the ability to
determine tropism from pvDNA allows testing to be ex-
tended to persons who are on effective antiretroviral ther-
apy but who may be candidates for CCR5 antagonist
therapy. This includes patients who are experiencing ad-
verse effects from their current regimen and patients re-
ceiving complex regimens who may benefit from regimen
simplification. In a pilot study of virologically suppressed
patients who were switched to a maraviroc-containing regi-
men after a R5 pvDNA genotypic tropism test result, 82%
of patients remained suppressed after 12 months [18].
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genotypic tropism assay using whole blood and PBMCs
from HIV-1 infected subjects. Although this was a small
study, a high degree of concordance was demonstrated
between pvDNA and plasma viral RNA tropism determi-
nations. This genotypic pvDNA tropism test may be use-
ful as a surrogate for plasma RNA tropism testing to
screen patients with suppressed or low level viremia for
CCR5 antagonist eligibility. Additional clinical studies
will be useful to further validate this approach. Further-
more, this assay may have value as a research tool for
the examination of proviral HIV DNA in PBMCs.Methods
Subject population
CARES is located in Sacramento, CA, and is affiliated
with the University of California, Davis, Medical Center.
It serves approximately 2,400, ethnically diverse, HIV-
infected patients in an outpatient setting. Fifty-percent
of the patients are non-Caucasian; 24% are Black/Afri-
can-American, 18.6% Hispanic/Latino, 2.9% American
Indian/Alaska Native, and 3.3% Asian/Native Hawaiian/
Pacific Islander. Eighty-one percent are men, 18% are
women and 1% are transgender. Approximately half of the
patients (54%) are between the ages of 30–50 years old.
The reported routes for HIV infection among the CARES
population include: 58% men who have sex with men
(MSM), 22% heterosexual, 15% intravenous drug use, and
1.0% hemophilia/blood transfusion/vertical transmission.
For this study, eligible subjects were HIV-infected pa-
tients >18 years old drawn from the CARES population
with viral loads above 1000 HIV-1 RNA copies/mL.
Subjects could be antiretroviral treatment-naïve or
treatment-experienced. Forty-two HIV-positive subjects
volunteered for the study. In addition, 7 healthy HIV-
negative volunteers were chosen to provide negative
control samples. The study was approved by the Institu-
tional Review Board at the University of California,
Davis Medical Center and all subjects gave written in-
formed consent. All subjects received a US$5 gift card.Study design
The study was designed to evaluate a novel HIV-1 pvDNA
tropism assay developed in a clinical laboratory (Quest
Diagnostics Nichols Institute, San Juan Capistrano, CA,
USA) by assessing the concordance between pvDNA- and
plasma RNA-based tropism determinations in viremic pa-
tients. Three sample types for pvDNA extraction were
assessed: whole blood, separated PBMCs resuspended
in phosphate-buffered saline (PBS), and peripheral
blood mononuclear cells (PBMCs) resuspended in spun
plasma (Figure 2). Plasma viral load and total, CD4
lymphocyte counts were also determined to gaugepossible effects on the assay success rate or on concord-
ance between sample types.
Sample collection and preparation
Samples were collected between November 2011 and
August 2012 at the CARES clinic from 42 HIV-positive
and 7 healthy HIV-negative volunteers. Whole blood for
pvDNA extraction and for lymphocyte count determina-
tions was drawn into two 4 mL EDTA Vacutainer tubes
(Becton Dickenson, Franklin Lakes, NJ, USA) and
shipped at room temperature (Figure 2: Tubes 1a and
1b). Whole blood was also drawn into two 8 mL CPT
Vacutainer tubes (Becton Dickenson). The tubes were
centrifuged at 800 g for 30 minutes. Up to 3 mL of
plasma for viral load determination and RNA tropism
testing were removed from the first tube, transferred to
an EDTA tube, and stored frozen at -70C (Figure 2:
Tube 2a). To obtain PBMCs for pvDNA tropism testing,
extra plasma was removed without disturbing the cell
layer above the gel barrier; 0.5 mL PBS was then added
to the CPT tube to resuspend the cell layer, which was
transferred to a cryovial and stored frozen at -70C
(Figure 2: Tube 2b). A further PBMC sample was ob-
tained from the second spun CPT Vacutainer tube. The
upper layer, containing the separated plasma and cell layer,
was gently mixed and then transferred into a 15 mL con-
ical tube and stored frozen at -70C (Figure 2: Tube 3).
Plasma viral load measurements and lymphocyte counts
HIV-1 plasma RNA viral loads were determined using
the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1
test, version 2.0 (Roche Diagnostics Corp., Indianapolis,
IN, USA). CD4+ and CD8+ T-cell percentages and abso-
lute counts were determined by flow cytometry and
standard hematological methods. These assays were per-
formed at Quest Diagnostics Nichols Institute, San Juan
Capistrano, CA, USA.
Plasma RNA tropism determination
Tropism was determined for 3 independent replicates of
viral RNA essentially as described elsewhere [2]. In brief,
viral RNA extraction was performed, followed by reverse
transcription and first-round PCR with forward and re-
verse primers SQV3F1 (HXB2 genomic coordinates
6855–6878) and CO602 (HXB2 genomic coordinates
7786–7817) in 3 independent replicates. Second-round
PCR was performed with primers 2 F (HXB2 genomic
coordinates 7062–7084) and 2R (HXB2 genomic coordi-
nates 7350–7373). Population sequencing was performed
with the second round PCR primers. Sequences were
assembled with ReCALL software (BC Centre for Excel-
lence in HIV/AIDS, Vancouver, BC) [20] and the 105 nt
V3 loop region (codons 1–35) was utilized for tropism
Figure 2 Laboratory analysis of study samples. Samples were collected and prepared for tropism analysis as described in Methods.
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positive rate (FPR) of 10% (X4: FPR ≤10%) [21].
Proviral DNA tropism determination
Total DNA was extracted from 0.5 mL whole blood or
0.3 mL PBMCs resuspended in PBS or the patients’ plasma
on a Roche MagNA Pure system using the Large Volume
MagNA Pure LC DNA Isolation Kit (Roche Diagnostics
Corp.). Three independent replicates were amplified in 2
rounds of PCR and analyzed by population sequencing
using the same priming strategy that was used for HIV-1
RNA tropism determination. Tropism assignment was per-
formed with the geno2pheno algorithm at a 10% FPR asTable 2 Proviral DNA tropism assay performance characterist
Within assay precision1
Specimen type Whole blood PBMC
Tropism concordance3 100% 100%
DNA sequence concordance4 98.9% 98.9%
DNA copies/mL N/A N/A
1Three replicates of 3 clinical samples were tested in a single run. Two samples wer
2Three replicates of 3 clinical samples were tested on 3 different days in 3 runs. Tw
3The tropism classifications for all replicates were 100% concordant with the origina
4Nucleotide sequences for the replicates were compared to the consensus sequenc
for the differences.
5The sensitivity standards were prepared by diluting purified, quantitated 963 bp H
and the LOD95 values were determined by probit analysis.described for RNA tropism determination. A negative con-
trol sample (HIV-negative human plasma) was included in
all runs. Positive controls for tropism status consisted of an
R5 and an X4 first-round PCR amplicon prepared from
pvDNA isolated from commercially available cultured R5
and X4 HIV-1 strains. Within assay and between assay re-
producibility was 100% for tropism classification and the
limit of detection (LOD95) for amplification of the pvDNA
V3 loop was below 500 DNA copies/mL (Table 2).
Phylogenetic analysis
To rule out inter-sample contamination, all V3 se-
quences from viral RNA and pvDNA sample types, asics
Between assay precision2 LOD95
5
Whole blood PBMC Whole blood PBMC
100% 100% N/A N/A
99.0% 98.6% N/A N/A
N/A N/A 480 360
e classified as R5 and one was classified as X4.
o samples were classified as R5 and one was classified as X4.
l R5 or X4 classification.
e and differences were tabulated. Mixed base calls (K, M, R, S, W, Y) accounted
IV-1 proviral DNA amplicons in HIV-1 negative human whole blood or plasma
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ClustalX v2.0 [22] and a neighbor-joining phylogenetic
tree was created and visualized with DendroScope 3 [23].
Additional files
Additional file 1: Figure S1. Neighbor-joining phylogenetic tree for all
replicate V3 loops sequenced in this study. Circles: V3 sequences from
RNA; triangles: pvDNA V3 sequences from whole blood; squares: pvDNA
V3 sequences from PBMCs.
Additional file 2: Figure S2. Phylogenetic analysis of sample 43. Circles:
V3 sequences from RNA; triangles: pvDNA V3 sequences from whole
blood; squares: pvDNA V3 sequences from PBMCs.
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